Are anti-beta-glycoprotein-I antibodies markers for recurrent pregnancy loss in lupus anticoagulant/anticardiolipin seronegative women?
OBJECTIVE
Anti-beta(2)-Glicoprotein-1 antibodies (anti-beta(2)GPI-ab) have been related to recurrent miscarriage (RM) with conflicting results. The aim was to evaluate the role of anti-beta(2)-GPI-ab as unique biological marker in RM related to antiphospholipid (aPL).


METHODS
A cohort study that included 59 cases, divided in two groups, was designed: group 1 comprised 43 pregnant women with 'obstetric' antiphospholipid syndrome (APS) and group 2 included 16 cases with similar complaints but only having repeatedly anti-beta(2)-GPI-ab. Previous thrombosis and/or inherited thrombophilia were excluded. Lupus anticoagulant, anticardiolipin antibodies (aCA), anti-beta(2)-GPI-ab, and other autoantibodies were analyzed. Miscarriages, premature births, pre-eclampsia, live births, placental and systemic thromboses were studied.


RESULTS
No differences in previous obstetric complications were detected (P = 1.00-0.164). After the treatment, differences in number of obstetric complications were not seen (P = 1.00). Live births were similar in two groups (88.4% and 93.7%; P = 1.00). Placental thrombosis was equal in both groups, 93.3% versus 80% (P = 1.00).


CONCLUSIONS
These results suggest that anti-beta(2)-GPI-ab may be considered a biological marker for obstetric APS.
Alijotas-Reig
Jaume
J
Systemic Autoimmune Disease Unit, Department of Internal Medicine I, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 16297jar@comb.es
Casellas-Caro
Manel
M
Ferrer-Oliveras
Raquel
R
Llurba-Olive
Elisa
E
Hermosilla
Eduard
E
Vilardell-Tarres
Miquel
M
Cabero-Roura
Lluis
L
D000026:Abortion, Habitual / Q000209:etiology / Q000276:immunology*; D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers; D015331:Cohort Studies; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology; D053482:beta 2-Glycoprotein I / Q000276:immunology*
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D001323:Autoantibodies; D015415:Biomarkers; D017984:Enoxaparin; D016682:Lupus Coagulation Inhibitor; D010975:Platelet Aggregation Inhibitors; D053482:beta 2-Glycoprotein I; D001241:Aspirin